intravenous immunoglobulin (IVIG) 10% triple virally reduced solution
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for intravenous immunoglobulin (IVIG) 10% triple virally reduced solution, covering 2021-08-24 to 2021-08-24. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia) [Phase 2]